About Cellogen Therapeutics
Cellogen Therapeutics is a Healthcare company based in Delhi (India) founded in 2021 by Gaurav Kharya. CAR-T cell therapies are developed for cancer and metabolic diseases. Cellogen Therapeutics has raised $4.81 million across 3 funding rounds from investors including Natco Pharma and Kotak Alternate Asset Managers. The company has 1 employees. Its Indian entity Cellogen Therapeutics Private Limited reported revenue of ₹46.1 Lakh. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell.
Company details
Cellogen Therapeutics was founded in 2021 in Delhi, India, within the biotechnology sector. CAR-T cell-based therapies are developed by the company to address cancer and metabolic diseases. Operations focus on research and therapeutic innovation, with services centered on advanced cell treatments. The founder, Gaurav Kharya, leads efforts in this domain, targeting global health challenges through localized expertise.
- Headquarters Delhi, India
- Employees 1
- Founders Gaurav Kharya
- SectorsHealthcare
- Website cellogentherapeutics.com
- Social X
- Legal Name Cellogen Therapeutics Private Limited
- Date of Incorporation 08 Jun, 2021
- Jurisdiction Dadri, Uttar Pradesh, India
- Annual Revenue₹46.1 Lakh
FY 2025 · +306% YoY
- Net Loss-₹83.7 Lakh
FY 2025 · -182% margin
- EBITDA-₹34.9 Lakh
FY 2025 · -76% margin
- Total Equity Funding$4.81M (USD)
in 3 rounds
- Latest Funding Round$2M (USD), Series A
May 2026
- InvestorsNatco Pharma
& 1 more
- Employee Count1
Associated legal entities of Cellogen Therapeutics
Cellogen Therapeutics operates through Cellogen Therapeutics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cellogen Therapeutics Private Limited CIN U85300UP2021PTC202881 | Active | 08 Jun 2021 | Dadri, Uttar Pradesh | ₹0.5 Cr | 2 | View details |
Funding Insights of Cellogen Therapeutics
Cellogen Therapeutics has successfully raised a total of $4.81M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.81M
- Total Rounds 3
- Last Round Series A — $2M
- First Round $1.93M
(Jan 2024)
- Investors Count 2
All 3 funding rounds of Cellogen Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $2M | Series A | – | – | |
| Apr 2025 | $885,590 | Seed | – | Natco Pharma | – |
| Jan 2024 | $1.93M | Seed | – | Natco Pharma | – |
2 investors in total: 2 institutional.
Investors in Cellogen Therapeutics
Cellogen Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Natco Pharma and Kotak Alternate Asset Managers.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
APIs and finished dosage forms are developed and manufactured. | 1981 | natcopharma.co.in | Hyderabad, India | |
| kotakalternateasset.com |
Investor details for Cellogen Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Cellogen Therapeutics Private Limited (Cellogen Therapeutics)
Cellogen Therapeutics Private Limited is the primary company behind Cellogen Therapeutics. The board of Cellogen Therapeutics Private Limited currently have 2 directors; the longest-serving is Gaurav Kharya, appointed in 2021. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gaurav Kharya DIN 08147487 | Director | 08 Jun 2021 | 5 yrs 4 mo | Cellogen Therapeutics Private Limited |
| Tanveer Ahmad DIN 09724780 | Director | 15 Dec 2023 | 2 yrs 10 mo | Cellogen Therapeutics Private Limited |
People of Cellogen Therapeutics
1 people are tracked at Cellogen Therapeutics (1 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
| Founder | Leadership |
Complete people profiles for Cellogen Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Cellogen Therapeutics
Figures of Cellogen Therapeutics Private Limited, the primary company behind Cellogen Therapeutics, for FY 2025. Revenue was ₹46.1 Lakh (+306% year on year). Net loss was -₹83.7 Lakh (-182% margin). EBITDA was -₹34.9 Lakh (-76% margin). Revenue has grown at a compounded annual rate of +185% over three years.
- ₹46.1 LakhRevenue · FY 2025 · +306% YoY
- -₹83.7 LakhNet loss · -182% margin
- -₹34.9 LakhEBITDA · -76% margin
- ₹2.6 LakhPaid-up capital
- +185%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Cellogen Therapeutics Private Limited are on its company page.
Detailed financial statements for Cellogen Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cellogen Therapeutics
3 dated milestones of Cellogen Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Cellogen Therapeutics is founded.
- Funding First funding round of $1.9M.
- Funding Latest funding round, Series A, of $2.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellogen Therapeutics
Complete news archive for Cellogen Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellogen Therapeutics
Cellogen Therapeutics was founded in 2021 and raised its 1st funding round 3 years after it was founded.
Cellogen Therapeutics is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
Cellogen Therapeutics is a funded company, having raised a total of $4.81M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.93M, raised on Jan 2024.
Cellogen Therapeutics has 1 employees.
The primary company behind Cellogen Therapeutics, Cellogen Therapeutics Private Limited, reported revenue of ₹46.1 Lakh for FY 2025, up 306% year on year.
Cellogen Therapeutics was founded in 2021 in Delhi, India, within the biotechnology sector. CAR-T cell-based therapies are developed by the company to address cancer and metabolic diseases. Operations focus on research and therapeutic innovation, with services centered on advanced cell treatments. The founder, Gaurav Kharya, leads efforts in this domain, targeting global health challenges through localized expertise.
Cellogen Therapeutics has 2 investors. Key investors include Natco Pharma, and Kotak Alternate Asset Managers.
Cellogen Therapeutics operates through Cellogen Therapeutics Private Limited.
The legal entities of Cellogen Therapeutics currently have 2 directors, including Gaurav Kharya, Tanveer Ahmad.